SequelSEC

Biofrontera Inc. BFRI

Pharmaceutical Preparations · CIK 0001858685 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$12.00M
Fiscal year ended 2026-06-30
Operating income
-$524.00K
Fiscal year ended 2026-06-30
Free cash flow
-$1.66M
Fiscal year ended 2026-06-30

Biofrontera Inc. (BFRI) reported revenue of $12.00M and net income of -$604.00K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Biofrontera Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Biofrontera Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$12.00M$10.08M$17.10M$6.99M$9.03M$8.59M$12.56M$9.01M$7.84M$7.91M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$524.00K-$4.32M$4.56M-$6.28M-$5.08M-$4.55M-$1.71M-$4.96M-$5.07M-$5.47M
Net income-$604.00K-$4.75M$5.64M-$6.65M-$5.32M-$4.20M-$1.40M-$5.67M-$257.00K-$10.44M
Research & development$448.00K$900.00K$787.00K$854.00K$870.00K$1.21M$783.00K$669.00K$621.00K$17.00K
Weighted-average diluted sharesshares 12.92Mshares 11.68MUnavailableshares 10.78Mshares 9.35Mshares 8.87MUnavailableshares 5.77Mshares 5.09Mshares 3.62M
Pretax income-$581.00K-$4.75M$5.64M-$6.64M-$5.30M-$4.20M-$1.40M-$5.67M-$237.00K-$10.44M
Income tax expense$23.00KUnavailable$0$6.00K$21.00K-$1.00K-$3.00K$3.00K$20.00K$1.00K
Diluted EPS$-0.05$-0.41$0.63$-0.62$-0.57$-0.47$0.17$-0.98$-0.05$-2.88
Selling, general & administrative$9.63M$10.99M$8.52M$10.05M$10.53M$8.65M$8.20M$8.42M$7.92M$9.25M
General & administrative$4.40M$5.73M$6.30M$5.55M$6.46M$4.55M$4.98M$3.85M$3.28M$4.16M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Biofrontera Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$4.66M$6.32M$6.39M$3.42M$7.24M$1.78M$5.90M$2.87M$4.38M$3.82M
Total assets$24.06M$24.79M$28.56M$15.42M$20.14M$16.59M$22.10M$18.52M$21.57M$24.58M
Current assets$12.44M$13.16M$18.08M$14.41M$18.82M$15.33M$20.70M$16.93M$17.47M$20.16M
Total liabilities$18.11M$18.72M$18.08M$18.00M$24.81M$16.12M$17.67M$12.99M$10.66M$26.42M
Current liabilities$10.54M$10.92M$11.90M$12.55M$19.69M$10.96M$12.02M$11.03M$9.27M$14.04M
Total equity incl. NCI$5.96M$6.07M$10.48M-$2.58M-$4.67M$469.00K$4.43M$5.53M$10.91M-$5.42M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$1.10M$1.23M$1.43M$4.33M$4.03M$6.53M$6.65M$6.53M$3.95M$6.90M
Accounts receivable$5.54M$3.88M$7.29M$3.00M$3.96M$4.03M$5.32M$4.87M$3.50M$3.52M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Biofrontera Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$1.66M-$70.00K-$2.38M-$3.82M-$3.04M-$4.12M-$1.02M-$1.21M-$4.72M-$3.32M
Capital expenditures$0$5.00K-$1.00K-$1.00K$1.00K$3.00K$1.00K$0-$48.00K$57.00K
Investing cash flow$0-$5.00K$3.00M$1.00K-$1.00K-$3.00K-$1.00K$0UnavailableUnavailable
Financing cash flowUnavailableUnavailable$2.35M$0UnavailableUnavailable$4.05M-$298.00K$5.28M$5.80M
Net change in cash-$1.66M-$75.00K$2.98M-$3.82M$5.45M-$4.12M$3.03M-$1.51M$562.00K$2.47M
Stock-based compensation$263.00K$342.00K$289.00K$236.00K$187.00K$239.00K$299.00K$288.00K$204.00K$228.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$65.00K$55.00KUnavailableUnavailable$26.00K$29.00KUnavailableUnavailableUnavailableUnavailable

Derived

Biofrontera Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$1.66M-$75.00KUnavailableUnavailable-$3.05M-$4.12M-$1.02M-$1.21MUnavailable-$3.38M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-4.4%-42.8%26.7%-89.8%-56.2%-52.9%-13.6%-55.0%-64.7%-69.1%
FCF margin-13.8%-0.7%UnavailableUnavailable-33.7%-48.0%-8.1%-13.4%Unavailable-42.7%
SBC / revenue2.2%3.4%1.7%3.4%2.1%2.8%2.4%3.2%2.6%2.9%
Current ratio1.18x1.20x1.52x1.15x0.96x1.40x1.72x1.53x1.89x1.44x
Revenue YoY growth32.9%17.4%36.2%-22.5%15.2%8.5%18.5%1.3%34.0%-9.4%
Net margin-5.0%-47.1%33.0%-95.1%-59.0%-48.9%-11.1%-62.9%-3.3%-131.9%
R&D / revenue3.7%8.9%4.6%12.2%9.6%14.1%6.2%7.4%7.9%0.2%
CapEx / revenue0.0%0.0%-0.0%-0.0%0.0%0.0%0.0%0.0%-0.6%0.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailable0.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BFRI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2024-03-31

Difference 3570000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.